A
Anna Caroli
Researcher at Mario Negri Institute for Pharmacological Research
Publications - 89
Citations - 4046
Anna Caroli is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Autosomal dominant polycystic kidney disease & Medicine. The author has an hindex of 32, co-authored 75 publications receiving 3276 citations. Previous affiliations of Anna Caroli include University of Freiburg & European Society of Radiology.
Papers
More filters
Journal ArticleDOI
A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia
Pasquale Anthony Della Rosa,Chiara Cerami,Francesca Gallivanone,Annapaola Prestia,Anna Caroli,Isabella Castiglioni,Maria Carla Gilardi,Maria Carla Gilardi,Giovanni B. Frisoni,Karl J. Friston,John Ashburner,Daniela Perani +11 more
TL;DR: A significant statistical effect is found of the population-specific FDG template-based normalisation in key anatomical regions for each dementia subtype, suggesting that spatial normalization with the new template provides more accurate estimates of metabolic abnormalities for single-subject and group analysis, and therefore, a more effective diagnostic measure.
Journal ArticleDOI
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial
Anna Caroli,Norberto Perico,Annalisa Perna,Luca Antiga,Paolo Brambilla,Antonio Pisani,Bianca Visciano,Massimo Imbriaco,Piergiorgio Messa,Roberta Cerutti,Mauro Dugo,Luca Cancian,Erasmo Buongiorno,Antonio De Pascalis,Flavio Gaspari,Fabiola Carrara,Nadia Rubis,Silvia Prandini,Andrea Remuzzi,Andrea Remuzzi,Giuseppe Remuzzi,Piero Ruggenenti +21 more
TL;DR: These findings provide the background for large randomised controlled trials to test the protective effect of somatostatin analogues against renal function loss and progression to end-stage kidney disease.
Journal ArticleDOI
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
Annapaola Prestia,Anna Caroli,Wiesje M. van der Flier,Rik Ossenkoppele,Bart N.M. van Berckel,Frederik Barkhof,Charlotte E. Teunissen,Anders Wall,Stephen F. Carter,Michael Schöll,Il Han Choo,Agneta Nordberg,Philip Scheltens,Giovanni B. Frisoni +13 more
TL;DR: The core biomarker pattern is in line with the current pathophysiologic model of AD, and fully normal and fully abnormal pattern is associated with exceptional and universal development of dementia.
Journal ArticleDOI
MRI-Based Automated Computer Classification of Probable AD Versus Normal Controls
Simon Duchesne,Anna Caroli,Cristina Geroldi,Christian Barillot,Giovanni B. Frisoni,D. L. Collins +5 more
TL;DR: It is shown in the Appendix that determinants and scaled grey-level intensity are appreciably more robust to varying parameters in validation studies using simulated data, when compared to raw intensities or grey/white matter volumes.
Journal ArticleDOI
Sirolimus Therapy to Halt the Progression of ADPKD
Norberto Perico,Luca Antiga,Anna Caroli,Piero Ruggenenti,Giorgio Fasolini,Mariateresa Cafaro,Patrizia Ondei,Nadia Rubis,Olimpia Diadei,Giulia Gherardi,Silvia Prandini,Andrea Panozo,Rodolfo Flores Bravo,Sergio Carminati,Felipe Rodriguez De Leon,Flavio Gaspari,Monica Cortinovis,Nicola Motterlini,Bogdan Ene-Iordache,Andrea Remuzzi,Giuseppe Remuzzi +20 more
TL;DR: Sirolimus halted cyst growth and increased parenchymal volume in patients with ADPKD and whether these effects translate into improved long-term outcomes requires further investigation.